Key Takeaways
- Conference Pop: Arcutis Biotherapeutics stock jumped 11.19% on September 16, closing at $26.14, after management doubled down on its 2026 growth story at a Morgan Stanley healthcare conference.
- Split Sentiment: Seven analysts split 4 buys, 2 outperforms, and 1 hold, targeting a $37 mean.
- Model Gap: TIKR’s mid case values Arcutis Biotherapeutics stock at $102 by late 2030, a 291% total return from here.
- Thin Volume: Trading during the rally ran roughly 70% below Arcutis Biotherapeutics stock’s average session volume, a signal that existing shareholders reacting to management’s tone drove the pop more than fresh institutional buying did.
Arcutis Biotherapeutics stock just jumped on conference tone, not new data. Track what analysts and the model project next on TIKR for free →
Why Arcutis Biotherapeutics Stock Jumped 11% on a Reiterated Guidance Story
Arcutis Biotherapeutics (ARQT) stock jumped 11.19% on Wednesday, September 16, closing at $26.14, up $2.63, after CEO Frank Watanabe and his finance chief used a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference to talk up ZORYVE, the company’s psoriasis and dermatitis franchise. Nothing new hit the tape that day. No FDA action, no earnings print, no analyst downgrade forced a reaction. What moved the stock was tone.
Judah Frommer of Morgan Stanley pressed Watanabe directly on the $2.5 billion to $3 billion peak ZORYVE sales range the company has floated for over a year. Watanabe didn’t hedge. “We feel very confident about that,” he said, pointing to a jump from roughly 3.5% of topical patients currently on ZORYVE to a targeted 15% to 20% as the math behind the number. That’s a fivefold conversion runway management is willing to defend on stage, not just in a slide deck.
The rest of the session reinforced the same story. Management reiterated the $525 million to $540 million 2026 revenue guidance raised back in August, said Q3 sales would grow in absolute terms over Q2 despite the usual summer seasonality in skin disease, and confirmed the vitiligo Phase 2 readout stays on track for the fourth quarter. Watanabe also flagged that Arcutis now covers about a third of Medicare lives and remains the only branded non-steroidal on the Medicare formulary, a detail that matters given how much reimbursement friction has slowed rival launches.
Volume told a different story than the price chart did. Shares changed hands at roughly 70% below the average session volume even as the stock ripped higher, meaning the move looked more like existing holders bidding up conviction than new institutional money piling in. That distinction matters for what comes next: a low-volume repricing on reiterated guidance is fragile if the next print doesn’t match the tone.
Arcutis Biotherapeutics stock jumped on conviction, not a new catalyst. See the ZORYVE numbers behind that confidence on TIKR for free →
Arcutis Biotherapeutics Stock’s Target Keeps Climbing Even as Coverage Thins
Arcutis Biotherapeutics stock carries a split verdict heading into the back half of 2026. The seven analysts TIKR tracks split 4 buys, 2 outperforms, and 1 hold, and their mean target sits at $37, 42% above Wednesday’s $26 close.
That gap has been a fixture, not a blip. On June 30, 2025, the stock closed at $14 against a $21 mean target, a 51% gap. It nearly closed by December 2025, when the stock ran to $29 versus a $32 target, just 9% behind.
Arcutis Biotherapeutics stock then fell as low as $24 in the March 2026 snapshot even as the mean target held above $34, and it has stayed above that level every quarter since, reaching a fresh $37 high now on seven analysts, one fewer than the eight who covered the name last quarter. Analysts didn’t chase the stock down in March. They held their ground, and the price has since caught back up toward them.
TIKR Values Arcutis Biotherapeutics Stock at $102, Pricing In ZORYVE’s Full Run
TIKR’s mid case model values Arcutis Biotherapeutics stock at $102 by December 2030, implying 291% total return from the current price of $26, or 37% annualized over 4.3 years.
That annualized rate outruns almost anything else in mid-cap dermatology, where profitable, self-funded growth stories at ZORYVE’s revenue scale remain scarce.
The model’s conviction traces straight back to Wednesday’s conference math. A move from 3.5% ZORYVE penetration today to the 15% to 20% range Watanabe described would triple the franchise well past the Street’s $37 target, and TIKR’s $102 figure simply extends that same conversion curve further than analysts have been willing to underwrite so far.
The gap between the model and the Street comes down to how much of the topical steroid market ZORYVE actually takes, not a rounding error in either estimate.
TIKR’s model points to $102 and 291% return for Arcutis Biotherapeutics stock. Compare that math yourself on TIKR for free →
Should You Invest in Arcutis Biotherapeutics, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Arcutis Biotherapeutics, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Arcutis Biotherapeutics, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ARQT stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
